Home › Hidradenitis Suppurativa › Texas › Dallas
Hidradenitis Suppurativa clinical trials in Dallas, TX
5 studies for Hidradenitis Suppurativa are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
RecruitingPhase 2
- Oruka Therapeutics Investigative Site, Dallas
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
- Investigative Site US078, Dallas
- Investigative Site US010, Dallas
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
- UT Southwestern Medical Center, Department of Dermatology- Site Number : 8400022, Dallas
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
- Texas Dermatology Research Center, Dallas
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
RecruitingPhase 2
- Texas Dermatology Research Center, Dallas
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
More about Hidradenitis Suppurativa on MedlinePlus
Hidradenitis Suppurativa trials in other cities
- Boston, MA9 studies
- Tampa, FL7 studies
- Miami, FL6 studies
- New York City, NY5 studies
- Birmingham, AL5 studies
- Phoenix, AZ5 studies
- New Orleans, LA4 studies
- Santa Clarita, CA4 studies
- Scottsdale, AZ4 studies
- Durham, NC4 studies
- Minneapolis, MN4 studies
- Philadelphia, PA4 studies
Other studies in Dallas
- Breast Cancer55 studies
- Non-Small Cell Lung Cancer52 studies
- Metastatic Cancer42 studies
- Heart Failure42 studies
- Cancer (all types)37 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity30 studies
- Ovarian Cancer28 studies
- Lung Cancer27 studies
- Bladder Cancer27 studies
- Endometrial Cancer24 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.